What are Factor VIII replacement therapy drugs?

Factor VIII replacement therapy drugs are pharmacologic agents that share a common mechanism (typically targeting Factor VIII). 0 are currently marketed, with 4 more in clinical development.

Factor VIII replacement therapy

0 marketed 2 in Phase 3 2 in Phase 2

This page covers all Factor VIII replacement therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Factor VIII.

Targets

Factor VIII

Phase 3 pipeline (2)

PEGylated Recombinant Factor VIII · Baxalta now part of Shire · Hemophilia A
PEGylated Recombinant Factor VIII is a recombinant form of human factor VIII that is modified with polyethylene glycol (PEG) to prolong its half-life.
rIX-FP · CSL Behring · Hematology
rIX-FP is a recombinant, humanized monoclonal antibody that targets factor VIII to prevent bleeding in patients with hemophilia A.

Phase 2 pipeline (2)

BAY14-2222_Kogenate-FS FVIII · Bayer · Hematology
Factor VIII replacement therapy
ADYNOVI · Baxalta now part of Shire · Hematology
ADYNOVI is a recombinant human coagulation factor VIII, used to treat and prevent bleeding episodes in patients with hemophilia A.